Esperion (NASDAQ: ESPR) announced two moderated poster presentations from the CLEAR Outcomes trial at the American College of Cardiology 2026 Annual Scientific Session (ACC.26), March 28-30 in New Orleans.
Both analyses evaluate bempedoic acid in underrepresented populations: stroke incidence in statin-intolerant patients and cardiovascular outcomes in patients with autoimmune or inflammatory diseases.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ESPR
+0.74%
27 alerts
+0.74%News Effect
+2.7%Peak Tracked
-6.2%Trough Tracked
+$5MValuation Impact
$667.71MMarket Cap
0.7xRel. Volume
On the day this news was published, ESPR gained 0.74%, reflecting a mild positive market reaction.
Argus tracked a peak move of +2.7% during that session.
Argus tracked a trough of -6.2% from its starting point during tracking.
Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility.
This price movement added approximately $5M to the company's valuation, bringing the market cap to $667.71M at that time.
This announcement highlights two moderated poster presentations from the CLEAR Outcomes trial, focus...
Analysis
This announcement highlights two moderated poster presentations from the CLEAR Outcomes trial, focusing on stroke incidence in statin-intolerant patients and cardiovascular outcomes in autoimmune or inflammatory diseases at ACC.26 (March 28–30, 2026). It reinforces Esperion’s strategy around bempedoic acid and ACLY biology across diverse patient populations. In context of prior positive guideline endorsements and advancing programs, investors may watch for how these subgroup data support future label expansions and real-world uptake.
Japan Phase 3 trial met primary endpoint with significant LDL-C reduction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Clinical and guideline-related updates have typically produced modestly positive moves, with an average same-tag reaction of 4.3% and only one notable negative response.
Recent Company History
Over the past two years, ESPR’s clinical and guideline-related news has highlighted expanding use of bempedoic acid, from a successful Phase 3 trial in Japan (May 20, 2024) to FDA alignment on pediatric Phase 3 trials (Mar 20, 2025). Positive European and U.S. guideline endorsements and IP-protective settlements further strengthened the franchise. Today’s CLEAR Outcomes subgroup analyses at ACC.26 extend this pattern of leveraging existing data into new patient populations.
Key Terms
bempedoic acid, clear outcomes, statins, cardiometabolic, +4 more
8 terms
bempedoic acidmedical
"Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations"
Bempedoic acid is an oral medicine that helps lower LDL cholesterol by blocking a key step in the liver’s cholesterol production pathway; think of it as turning off a factory machine upstream so less product reaches the shelves. It matters to investors because regulatory approvals, clinical results, pricing, patent life and how widely doctors adopt the drug affect future sales and a company’s revenue prospects, similar to how a new popular product can change a firm’s market value.
clear outcomesmedical
"new insights from the CLEAR Outcomes trial among an audience"
Clear outcomes are specific, measurable results or end points that leave little doubt about whether an initiative — such as a clinical trial, product launch, or strategic program — succeeded or failed. They matter to investors because well-defined outcomes reduce uncertainty and make it easier to compare risks and rewards, like having a clearly marked finish line that tells you if the project reached its goal and how to value the company going forward.
statinsmedical
"need of Alternatives to Statins in Cardiovascular Risk Management"
Statins are a widely used class of prescription drugs that lower levels of cholesterol in the blood by blocking the biochemical step the body uses to make cholesterol; think of them as a filter that reduces material that can build up inside arteries. They matter to investors because prescribing rates, patent status, safety concerns, and regulatory approvals or label changes directly affect drug makers' sales, healthcare costs, and the outlook for companies that develop, manufacture, or compete with cholesterol-lowering therapies.
cardiometabolicmedical
"developing and delivering innovative cardiometabolic and rare/orphan disease therapies"
Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.
orphan diseasemedical
"innovative cardiometabolic and rare/orphan disease therapies"
A rare medical condition that affects a very small number of people, often so few that standard drug development and commercial sales are impractical. For investors it matters because treatments for these conditions can qualify for special regulatory incentives, faster approval paths and price premiums, so a successful therapy is like owning a product that dominates a tiny but underserved niche market — high potential reward but also higher scientific and commercial risk.
acly biologymedical
"The Company leverages deep domain expertise in ACLY biology"
ACLY biology concerns the role of the enzyme ATP citrate lyase (ACLY) in converting cell fuel into acetyl units used to build fats and modify proteins, essentially acting like a factory machine that turns raw energy into construction materials for cells. Investors care because ACLY is a common drug target for conditions such as metabolic disease, fatty liver and some cancers; changes in ACLY-related research or therapies can affect the value of companies developing treatments or diagnostics.
ldl-cmedical
"maintain their low-density lipoprotein cholesterol (LDL-C) levels"
LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.
primary sclerosing cholangitismedical
"including treatments for Primary Sclerosing Cholangitis and renal diseases"
A chronic disease in which the tubes that carry bile from the liver become inflamed and scarred, gradually blocking flow and potentially causing liver damage or failure; think of it like corrosion and narrowing in the body’s plumbing that disrupts normal cleanup and digestion. It matters to investors because there is no widely effective cure, so diagnostic advances, drugs, or procedures that slow progression can create meaningful commercial markets and clinical trial, regulatory and pricing risks that affect valuations in healthcare and biotech companies.
Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management
ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that two abstracts have been accepted for presentation in moderated poster sessions at the upcoming American College of Cardiology’s 2026 Annual Scientific Session (ACC.26) taking place March 28-30, 2026 in New Orleans, LA.
“ACC.26 provides an important platform to share new insights from the CLEAR Outcomes trial among an audience of the world’s leading cardiologists,” said Sheldon Koenig, Chief Executive Officer of Esperion. “These analyses deepen our understanding of cardiovascular risk reduction in patients with other co-morbidities who are often underrepresented in traditional studies and reinforce our mission to deliver meaningful therapeutic options for diverse patient populations who need alternatives to statins.”
Moderated Presentations
Title:
Session: Location: Date & Time: Authors:
Presenter:
Bempedoic Acid and Incidence of Stroke Among Statin-Intolerant Patients: An Analysis of The Clear Outcomes Trial 1069 Moderated Poster Theatre 06, Posters, Hall E Saturday, March 28, 2026, 4:18 – 4:25 pm ET C. Pires Zingano, D. Brennan, M. Li, W. Sasiela, L. Bloedon, S.E. Nissen, L.J. Laffin Carolina Pires Zingano, MD (Cleveland Clinic)
Title:
Session: Location: Date & Time: Authors:
Presenter:
Bempedoic Acid and Cardiovascular Outcomes in Patients with Autoimmune or Inflammatory Diseases: An Analysis of the Clear Outcomes Trial 1084 Moderated Poster Theater 05, Posters, Hall E Sunday, March 29, 2026, 9:30 – 9:37 am ET B. Frison Spiazzi, B. Weber, D. Brennan, L. Bloedon, M. Li, S.E. Nissen, L.J. Laffin Bernardo Frison Spiazzi, MD (Cleveland Clinic)
Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
What will Esperion (ESPR) present at ACC.26 on March 28-30, 2026?
Esperion will present two moderated poster analyses from CLEAR Outcomes focusing on bempedoic acid in special populations. According to the company, sessions examine stroke incidence in statin-intolerant patients and cardiovascular outcomes in autoimmune or inflammatory disease patients, with named presenters and scheduled times.
When and where is the Esperion (ESPR) poster on stroke incidence presented at ACC.26?
The stroke incidence poster is scheduled for March 28, 2026, at 4:18–4:25 pm ET in Hall E. According to the company, Carolina Pires Zingano, MD (Cleveland Clinic) is listed as the presenter for the moderated poster theatre session.
What is the focus of the Esperion (ESPR) CLEAR Outcomes analysis for autoimmune or inflammatory disease patients?
The analysis evaluates cardiovascular outcomes with bempedoic acid in patients with autoimmune or inflammatory diseases. According to the company, the moderated poster will present data at ACC.26 on March 29, 2026, with Bernardo Frison Spiazzi, MD listed as presenter.
How do these CLEAR Outcomes presentations affect Esperion's position on non-statin therapies (ESPR)?
The presentations aim to deepen evidence for bempedoic acid in populations needing statin alternatives. According to the company, the analyses reinforce Esperion’s mission to offer therapeutic options for diverse, underrepresented cardiovascular-risk populations.
Where can investors find more information about Esperion (ESPR) and the ACC.26 presentations?
Investors can review Esperion’s investor contact details and company information for follow-up and materials. According to the company, investor relations and media contacts are provided for inquiries and further details on the presentations and data.
